AstraZeneca is investing $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes an expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials.

The investment will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 highly skilled jobs.

The planned expansion of the Frederick Facility will nearly double commercial manufacturing capacity, enabling increased supply of existing medicines and, for the first time, production across the company’s rare disease portfolio. In parallel, AstraZeneca will build a new clinical manufacturing facility to expand its footprint in Gaithersburg.

Both the expanded facility in Frederick and the new facility in Gaithersburg will leverage cutting-edge AI, automation and data analytics and be built to the highest environmental standards.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalyzing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the U.S. medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”

Today’s announcement is part of AstraZeneca’s $50 billion investment announced in July and follows a series of U.S. commitments over the past six months.